- FDA grants accelerated approval for advanced non-small cell lung cancer treatment
- The quiet crisis: why medicines operations matter more than ever in the ICB era
- Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
- Nick Challoner appointed CEO of Ingenza to drive further growth
- Biocon Biologics gains EU approval for bone health therapies
- Ferring strengthens evidence for flexible dosing of follitropin delta in IVF
- Carthera receives EMA endorsement for orphan medical device status of SonoCloud
- SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant
- PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
- FDA approves Gamifant for macrophage activation syndrome in Still’s disease
- Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development
- Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
- STENTiT treats first patient with regenerative stent for limb preservation
- Inizio Evoke appoints Kelly Cusumano to drive strategic growth and innovation
- Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases